Related Experiment Videos
[Tumor markers in uterine cancers].
Ichio Fukasawa1, Nobuaki Kousaka, Zu Kun
1Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 28, 2002
Summary
Cytologic and histologic investigation are key for early uterine cancer detection. Tumor markers aid in monitoring treatment and recurrence, with combined markers showing promise for uterine corpus carcinoma.
Area of Science:
- Gynecologic Oncology
- Biomarker Research
- Cancer Diagnostics
Context:
- Uterine cancers require accurate diagnostic methods for effective management.
- Direct sampling of lesions allows for cytologic and histologic analysis.
- Early detection significantly improves patient prognosis and treatment outcomes.
Purpose:
- To evaluate the role of cytologic, histologic, and tumor marker investigations in diagnosing and monitoring uterine cancers.
- To assess the utility of specific tumor markers like squamous cell carcinoma-associated antigen (SCC) and cancer antigen 125 (CA125).
- To explore the potential of combined tumor marker assays for uterine corpus carcinoma.
Summary:
- Cytologic and histologic examinations are the primary methods for screening and early detection of primary uterine cancers.
- Tumor markers are valuable for monitoring therapy and detecting recurrence when cytologic examination is not feasible.
- While not entirely tumor-specific, elevated tumor markers can indicate invasiveness, metastasis, and poor prognosis. SCC is relatively specific for squamous cell carcinoma, but no single marker exists for uterine corpus carcinoma.
- A combination assay, potentially including CA125, may enhance diagnostic value for uterine corpus carcinoma.
Impact:
- Provides insights into optimal diagnostic strategies for uterine cancers.
- Highlights the complementary roles of traditional pathology and novel biomarker approaches.
- Informs clinical practice regarding the use of tumor markers for prognosis and monitoring, particularly for uterine corpus carcinoma.